[1] 赫捷,陈万青,李霓,等. 中国前列腺癌筛查与早诊早治指南(2022,北京)[J]. 中国肿瘤,2022,31(1):1-30. DOI:10.11735/j.issn.1004-0242.2022.01.A001.
[2] Distler FA, Radtke JP, Bonekamp D, et al. The value of PSA density in combination with PI-RADS™ for the accuracy of prostate cancer prediction[J].J Urol,2017,198(3):575-582. DOI:10.1016/j.juro.2017.03.130.
[3] Epstein JI, Egevad L, Amin MB, et al. The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system[J].Am J Surg Pathol,2016,40(2):244-252. DOI:10.1097/PAS.0000000000000530.
[4] Loeb S, Sanda MG, Broyles DL, et al. The prostate health index selectively identifies clinically significant prostate cancer[J].J Urol,2015,193(4):1163-1169. DOI:10.1016/j.juro.2014.10.121.
[5] 周占松.前列腺特异性抗原筛查前列腺癌:继续深入或时代终结[J].第三军医大学学报,2013,35(15):1545-1547. DOI:10.16016/j.1000-5404.2013.15.020.
[6] 朱蜀宁. 前列腺特异抗原定性检查和直肠指检在前列腺癌社区普查的意义研究[J]. 中国全科医学,2012,15(17):1921-1923. DOI:10.3969/j.issn.1007-9572.2012.06.046.
[7] Tasian GE, Cooperberg MR, Potter MB, et al. PSA screening: determinants of primary-care physician practice patterns[J].Prostate Cancer Prostatic Dis,2012,15(2):189-194. DOI:10.1038/pcan.2011.59.
[8] 王炜,李传刚,刘辉,等. 前列腺特异性抗原对前列腺癌诊断价值的探讨[J]. 中国医科大学学报,2016,45(1):61-65,69. DOI:10.12007/j.issn.0258-4646.2016.01.014.
[9] 侯瑞军. 游离/总前列腺特异性抗原比值对早期诊断前列腺癌的观察[J]. 山西医药杂志,2012,41(21):1156-1157.
[10] Seaman E, Whang M, Olsson CA, et al. PSA density (PSAD). Role in patient evaluation and management[J].Urol Clin North Am,1993,20(4):653-663.
[11] Verma A, St Onge J, Dhillon K, et al. PSA density improves prediction of prostate cancer[J].Can J Urol,2014,21(3):7312-7321.
[12] Tang P, Du W, Xie K, et al. Transition zone PSA density improves the prostate cancer detection rate both in PSA 4.0-10.0 and 10.1-20.0 ng/ml in Chinese men[J].Urol Oncol,2013,31(6):744-748. DOI:10.1016/j.urolonc.2011. 06.012.
[13] American College of Radiology. Prostate imaging and report and data system (PI-RADS)[EB/OL].[2022-03-15]. http://www.acr.org/Quality-Safety/Resources/PIRADS.
[14] Purysko AS, Bittencourt LK, Bullen JA, et al. Accuracy and interobserver agreement for prostate imaging reporting and data system, version 2, for the characterization of lesions identified on multiparametric MRI of the prostate[J].AJR Am J Roentgenol,2017,209(2):339-349. DOI:10.2214/AJR.16.17289.
[15] Greer MD, Brown AM, Shih JH, et al. Accuracy and agreement of PIRADSv2 for prostate cancer mpMRI: a multireader study[J].J Magn Reson Imaging,2017,45(2):579-585. DOI:10.1002/jmri.25372.
[16] 王良. 前列腺影像报告和数据系统(PI-RADS V2.1)解读[J]. 中华放射学杂志,2020,54(4):273-278. DOI:10.3760/cma.j.cn112149-20190429-00382.
[17] 汪洋,宦怡,任静. 前列腺影像报告与数据系统2.1版(PI-RADS v2.1):解读与比较[J]. 国际医学放射学杂志,2019,42(6):712-716. DOI:10.19300/j.2019.B7481.
[18] Mimata H, Satoh F, Ohno H, et al. Clinical characteristics of alpha-blocker responders in men with benign prostatic hyperplasia[J].Urol Int,2002,68(4):237-242. DOI:10.1159/000058442.
[19] Hötker AM, Blüthgen C, Rupp NJ, et al. Comparison of the PI-RADS 2.1 scoring system to PI-RADS 2.0: impact on diagnostic accuracy and inter-reader agreement[J].PLoS One,2020,15(10):e0239975. DOI:10.1371/journal.pone. 0239975.
[20] Padhani AR, Weinreb J, Rosenkrantz AB, et al. Prostate Imaging-Reporting and Data System Steering Committee: PI-RADS v2 status update and future directions[J].Eur Urol,2019,75(3):385-396. DOI:10.1016/j.eururo.2018. 05.035.
[21] Boesen L, Nørgaard N, Løgager V, et al. Assessment of the diagnostic accuracy of biparametric magnetic resonance imaging for prostate cancer in biopsy-naive men: the biparametric MRI for detection of prostate cancer (BIDOC) study[J].JAMA Netw Open,2018,1(2):e180219. DOI:10.1001/jamanetworkopen.2018.0219.
[22] Lee SJ, Oh YT, Jung DC, et al. Combined analysis of biparametric MRI and prostate-specific antigen density: role in the prebiopsy diagnosis of Gleason score 7 or greater prostate cancer[J].AJR Am J Roentgenol,2018,211(3):W166-W172. DOI:10.2214/AJR.17.19253.
[23] Thestrup KC, Logager V, Baslev I, et al. Biparametric versus multiparametric MRI in the diagnosis of prostate cancer[J].Acta Radiol Open,2016,5(8):2058460116663046. DOI:10.1177/2058460116663046.
[24] Kandıralı E, Temiz MZ, Çolakerol A, et al. Does the prostate volume always effect cancer detection rate in prostate biopsy? Additional role of prostate-specific antigen levels: a retrospective analysis of 2079 patients[J].Turk J Urol,2018,45(2):103-107. DOI:10.5152/tud.2018.66909.
[25] McNeal JE, Redwine EA, Freiha FS, et al. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread[J].Am J Surg Pathol,1988,12(12):897-906. DOI:10.1097/00000478-198812000- 00001.
[26] Patel P, Wang S, Siddiqui MM. The use of multiparametric magnetic resonance imaging (mpMRI) in the detection, evaluation, and surveillance of clinically significant prostate cancer (csPCa)[J].Curr Urol Rep,2019,20(10):60. DOI:10.1007/s11934-019-0926-0.
[27] Tamada T, Kido A, Takeuchi M, et al. Comparison of PI-RADS version 2 and PI-RADS version 2.1 for the detection of transition zone prostate cancer[J].Eur J Radiol,2019,121:108704. DOI:10.1016/j.ejrad.2019. 108704.
[28] 史旭波,黄贵生,黎晓蓉,等.前列腺癌患者的多模态磁共振功能成像研究[J].现代医院,2020,20(8):1243-1246. DOI:10.3969/j.issn.1671-332X.2020.08.045.
[29] 魏晓婷,钟淑媛,胡根文,等. 前列腺影像报告和数据系统2.1版联合临床指标对前列腺癌的诊断价值[J]. 中国医学影像学杂志,2021,29(4):390-394. DOI:10.3969/j.issn. 1005-5185.2021.04.025.
[30] 中华医学会泌尿外科分会. 前列腺癌诊断治疗指南[J]. 继续医学教育,2007,21(6):30-39. DOI:10.3969/j.issn.1004- 6763.2007.06.010.
|